Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265199 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)
A Phase 1 study, sponsored by Ascenta Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01265199 is a Phase 1 study that was terminated before completion, run by Ascenta Therapeutics. The registered enrollment target is 29 participants.
The verdict
NCT01265199, a Phase 1 study, was terminated before completion, sponsored by Ascenta Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The main purpose of this study are to determine the maximum dose of AT-406 that can be safely given in combination with cytarabine and daunorubicin to humans. Other purposes are to determine how the drug is broken down in the body, and to see if there are any molecular interactions that can help determine how AT-406 works. Side effects will also be studied in an effort to make sure that this drug is safe to take.
Interventions
- DRUG AT-406 in combination with daunorubicin and cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265199
The ClinicalTrials.gov registry entry for NCT01265199 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascenta Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AT-406 in combination with daunorubicin and cytarabine is the first listed.
NCT01265199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265199 about?
NCT01265199 is a clinical study titled "Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)". The main purpose of this study are to determine the maximum dose of AT-406 that can be safely given in combination with cytarabine and daunorubicin to humans. Other purposes are to determine how the drug is broken down in the body, and to see if there are any molecular interactions that can help det...
What is the current status of trial NCT01265199?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2011-02. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01265199?
The interventions under investigation include: AT-406 in combination with daunorubicin and cytarabine (DRUG).
Who is sponsoring clinical trial NCT01265199?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.